by Sue Robbins | Jan 27, 2020 | Migraine
Treatment with the orally administered, small-molecule calcitonin gene-related peptide receptor antagonist ubrogepant in patients with acute migraine has been associated with freedom from pain and the absence of the patient-determined most troublesome symptom compared...
by Sue Robbins | Dec 26, 2019 | Migraine
The FDA has approved ubrogepant (Ubrelvy; Allergan) for the acute treatment of migraine with or without aura in adults, making it the first-in-class oral calcitonin gene-related peptide (CGRP) antagonist for this indication.1 The new drug application (NDA) was...
by Sue Robbins | Dec 18, 2019 | Migraine
A study in the Journal of the American Medical Association indicates that ubrogepant demonstrated greater rates of pain and symptom relief from migraine compared with a placebo. More than 20% of participants in a large-scale clinical trial reported being pain-free...
by Sue Robbins | Aug 20, 2019 | Migraine
Ubrogepant has demonstrated efficacy in treating acute migraine among individuals for whom triptan has not been effective. Read more here.
